Australian Prescriber is much loved by you, its readers, and justifiably so. You have said in many readership surveys over the years that you value the quality of the content and the concise easy-to-read format. I know that you appreciate the ‘without fear or favour’ approach the journal takes, on both clinical and policy matters.

Some 53 000 health professionals receive Australian Prescriber including about 12 000 GPs, 9000 medical specialists and 14 000 pharmacists. It is popular internationally and the website has had a high rate of hits.

So why has NPS MedicineWise decided to make changes to this icon of Australian medical publishing and why now? It could be seen as a contentious decision and requires scrutiny because the future of Australian Prescriber is something we all care about. NPS MedicineWise has been the custodian of the journal since 2002 and we know it is one of our most valuable products.

At 40 years old, the journal remains as vital and effective as at inception. It has retained its relevance over the years by being connected with the readers, adapting to change and regularly introducing innovations. Australian Prescriber was one of the first Australian medical journals to go online. It was early to introduce mobile access and last year it produced its first app, The Doctor’s Bag.

Australian Prescriber is run very efficiently by a small team of passionate and talented people. It has a thorough editorial process that adds tremendous value to the articles it commissions. It has strong and enduring relationships with some of the best medical and pharmacy minds in the country. I believe these three key components are critical to the quality, credibility and utility of Australian Prescriber. These are the things that I trust will never be compromised. However, maintenance of these critical features of Australian Prescriber’s operations sits on a background of gradually increasing costs and a slightly smaller funding envelope for NPS MedicineWise in the coming years. We want to continue to innovate, grow the readership and keep pace with changes in medical publishing, and to succeed we need to reallocate resources.

On this basis, I have taken the decision to cease print publication and distribution. While I know many readers will miss the hard copy, I encourage you to tell us what formats will work best for you in a digital world. In 2012, doctors were spending an average of six hours per week online and had high levels of access to computers, tablets and smart phones.1 An NPS MedicineWise survey in 2012 found that 55% of GPs prefer to do self-education online.2 More recent data from the wider community would lead us to believe this connectivity has increased. A Nielson poll in December 2015 reported that over 18 million Australians use the internet. They spend 30 hours on average per week online and the growing areas of use are mobile phones and tablets, now making up 69% of all use.3

The future for Australian Prescriber is bright. It will remain an important medical journal here and internationally. One of the early challenges will be to increase email subscriptions to reach existing readers and also find new readers. For example, our circulation numbers show that not all GPs have signed up to receive Australian Prescriber in print. I hope we can move towards 100% of GPs reading the journal online.

Making the journal available when and how readers find most convenient is likely to mean expanding to some new media formats. The Australian Prescriber team will be undertaking evaluation to learn more about the best ways to bring digital content to you, whatever your needs.

There will be opportunities to bring articles together to support students and practitioners with particular questions or needs. The journal will also be looking for ways to support new prescribers, whatever their profession.

Australian Prescriber will continue to be essential reading for everyone wanting to stay up to date with drugs and therapeutics.

Conflict of interest: Lynn Weekes is the chief executive officer of NPS MedicineWise.